Prognostic value of metabolic tumor burden calculated using dual-time-point 18F-fluorodeoxyglucose positron emission tomography/CT in patients with oropharyngeal or hypopharyngeal cancer.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 30537436.
- Also identified by DOI 10.1002/hed.25490.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This study investigates the prognostic value of metabolic tumor burden calculated using dual-time-point 18F-fluorodeoxyglucose positron emission tomography (FDG-PET)/CT in patients with locally advanced cancer. This study examines 42 patients (35 men and 7 women, 38-73 years old) with locally advanced oropharyngeal or hypopharyngeal cancer who had undergone FDG-PET/CT before receiving chemoradiotherapy. Maximum standardized uptake value (SUV<sub>max</sub> ), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were measured for the early and delayed phases. Statistical analyses included receiver operating characteristic curve, univariate and multivariate analysis. ΔSUV<sub>max</sub> , both phases of MTV<sub>2.5</sub> and TLG<sub>2.5</sub> , early TLG<sub>40%</sub> , ΔTLG<sub>2.5</sub> , and ΔTLG<sub>40%</sub> were significantly associated with progression-free survival (PFS). In multivariate analysis, early TLG<sub>2.5</sub> (P = .005) was an independent prognostic factor of PFS. Not the percent change but the value calculated in the early phase in several parameters using dual-time-point FDG-PET/CT is significantly associated with the outcomes of patients with locally advanced oropharyngeal or hypopharyngeal cancer.
Medical subject headings
- Hypopharyngeal Neoplasms
- Oropharyngeal Neoplasms
- Tumor Burden